AEM Stats & Data

PiHKAL reports AEM ('alpha‑Ethyl‑3,4,5‑trimethoxy‑PEA') as sub‑threshold with no psychoactive effects up to 220 mg oral; Shulgin’s overview also notes it proved inactive even at the hundreds of milligrams level, so it was not pursued further. Because authentic AEM appears inactive at typical 'psychedelic' testing ranges, any material sold as 'AEM' that produces clear psychedelic or stimulant effects may be mislabelled or adulterated; drug checking is strongly advised where available. Unknown novel powders are frequently misdeclared in street and online markets, and harm‑reduction agencies repeatedly document samples containing unexpected actives; assume identity uncertainty until analytically verified. If a person insists on test‑dosing for identification, perform an allergy test first (≈1 mg), wait several hours, and use a calibrated milligram scale or volumetric dosing to avoid accidental overdosing; inaccurate measurement is a common cause of emergencies with research chemicals. Avoid non‑oral routes (insufflation, injection, rectal) for unknown phenethylamines due to faster kinetics, uncertain potency, and greater adverse event risk. Do not combine with MAOIs, tramadol, or additional stimulants in case the substance is an active phenethylamine; several psychedelic phenethylamine combinations are flagged as caution/unsafe by harm‑reduction guides. Absence of effect at 220 mg does not imply safety at higher doses; idiosyncratic reactions or contamination remain possible. Legal status varies; possession or synthesis may be illegal. There are no pharmacokinetic data or clinical safety data for AEM in humans.